06/06/2025 | Press release | Distributed by Public on 06/06/2025 12:29
Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
Applied DNA Sciences, Inc. (the "Company") received written notice dated May 30, 2025 (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company no longer satisfies the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the "Bid Price Rule"). Based on the closing bid price of the Company's common stock, par value $0.001 per share ("Common Stock"), for the thirty-two (32) consecutive business days from April 14, 2025 to May 29, 2025, the Company no longer satisfies the Bid Price Rule.
As previously disclosed, at 12:01 a.m. Eastern Time on June 2, 2025, the Company effected a 1-for-15 reverse stock split of the Common Stock in an effort to regain compliance with the Bid Price Rule. To do so, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of ten (10), but generally not more than twenty (20), consecutive business days.
The Notification Letter further indicated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one; accordingly, the Company was informed that its securities were subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel"). Today, the Company timely requested a hearing, which request will stay any further suspension or delisting action by Nasdaq at least pending the ultimate conclusion of the hearing process. There can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq.